ENV-6946
/ Enveda Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 24, 2025
Enveda, a clinical-stage biotech pioneering a new generation of small-molecule drugs, has announced that the US FDA has cleared its Investigational New Drug (IND) application for a first-in-class oral therapy for Inflammatory Bowel Disease (IBD).
(Indian Pharma Post)
- "Following this clearance, Enveda has officially initiated a Phase 1 clinical trial for ENV-6946."
IND • New P1 trial • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1